🇺🇸 FDA
Pipeline program

Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

CNTO1959PUC3001

Phase 3 small_molecule active

Quick answer

Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml for Ulcerative Colitis is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Ulcerative Colitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials